DCAN BioSciences develops a microfluidic device for the isolation and analysis of circulating tumor cells (CTCs) and CTC clusters (CTCCs) to enhance cancer diagnosis and monitoring. This technology enables pathologists to perform accurate liquid biopsies by assessing the molecular signatures of both single and clustered tumor cells.
Funding
Funding not disclosed
Founders
Product
Problem
Current methods for isolating and analyzing circulating tumor cells (CTCs) and CTC clusters (CTCCs) often lack the precision needed for accurate cancer diagnosis and monitoring. Existing technologies may not effectively capture and differentiate between single CTCs and CTCCs, hindering comprehensive molecular profiling.
Solution
DCAN BioSciences is developing a microfluidic platform designed for the enhanced isolation and analysis of both circulating tumor cells (CTCs) and CTC clusters (CTCCs) from liquid biopsies. The device aims to provide pathologists with a more accurate and detailed assessment of tumor cell characteristics. By enabling the separation and molecular analysis of single CTCs and CTCCs, the technology seeks to improve cancer diagnosis, prognosis, and treatment monitoring. The platform intends to offer a comprehensive view of the tumor's cellular composition, facilitating personalized medicine approaches.
Target Audience
The primary target audience includes pathologists and oncologists involved in cancer diagnostics and personalized medicine.
Features
- Microfluidic chip for high-resolution separation of CTCs and CTCCs
- Enhanced capture efficiency for rare circulating tumor cells
- Integrated analysis module for molecular profiling of isolated cells